Sign in

You're signed outSign in or to get full access.

BI

Bioventus Inc. (BVS)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 revenue of $123.9M declined 4.3% YoY due to the late-2024 divestiture, but organic revenue grew 5.0%; Non-GAAP EPS was $0.08 (+33% YoY) and Adjusted EBITDA was $19.2M, down primarily on divestiture impact and planned growth investments .
  • Results modestly beat consensus: revenue $123.9M vs $122.7M*, and Non‑GAAP EPS $0.08 vs $0.023*, with segment strength in DUROLANE (double-digit growth) and Ultrasonics (double-digit growth) partly offset by channel inventory normalization and an FX revaluation loss .
  • 2025 guidance was reaffirmed: net sales $560–$570M, Adjusted EBITDA $112–$116M, Non‑GAAP EPS $0.64–$0.68; tariffs now included and expected to be immaterial (<$1M) .
  • Potential stock reaction catalysts: reiterated FY guide with second-half acceleration narrative, ongoing share gains in HA and Ultrasonics, PRP portfolio addition, and leverage trajectory toward ≤2.5x by year-end 2025 .

What Went Well and What Went Wrong

  • What Went Well

    • DUROLANE (single-injection HA) delivered double‑digit growth; management highlighted strong clinical value proposition, contract backbone, and dedicated commercial execution supporting above‑market growth .
    • Ultrasonics grew double‑digits on strong U.S. capital equipment purchases; Surgical Solutions revenue advanced 7% in Q1 .
    • Non‑GAAP EPS increased 33% YoY to $0.08, aided by peer‑leading gross margin and lower interest expense, and the company reiterated full‑year revenue, Adjusted EBITDA and EPS guidance .

  • What Went Wrong

    • Reported revenue declined 4.3% YoY from the 2024 Advanced Rehabilitation divestiture; Adjusted EBITDA decreased to $19.2M from $22.6M .
    • Q1 cash from operations was an outflow of $19.3M due to timing of annual bonuses and other annual costs (~$27M), though management expects acceleration starting Q2 .
    • FX revaluation loss (~$1.1M) on Swedish krona payables and channel mix/freight pressures weighed on adjusted gross margin (down ~70 bps YoY) .

Financial Results

  • Quarterly results and trajectory
MetricQ3 2024Q4 2024Q1 2025
Revenue ($M)$139.0 $153.6 $123.9
GAAP Gross Margin (%)67.3% 66.8% 67.0%
Non‑GAAP Gross Margin (%)74.7% 73.7% 75.3%
Adjusted EBITDA ($M)$23.6 $28.3 $19.2
GAAP EPS (Continuing)$(0.07) $0.00 $(0.04)
Non‑GAAP EPS$0.06 $0.15 $0.08
  • Results vs. estimates (Q1 2025)
MetricActualConsensus*Surprise
Revenue ($M)$123.9 $122.7*+$1.2M
Non‑GAAP EPS$0.08 $0.023*+$0.06
  • Segment breakdown (global)
Segment ($M)Q3 2024Q4 2024Q1 2025
Pain Treatments$63.1 (56.306 US + 6.821 Int’l) $69.2 (62.799 + 6.414) $58.9 (52.686 + 6.232)
Surgical Solutions$45.9 (41.155 + 4.745) $53.7 (46.431 + 7.293) $45.2 (40.844 + 4.390)
Restorative Therapies$29.9 (25.448 + 4.489) $30.7 (25.980 + 4.725) $19.7 (16.990 + 2.734)
Total$139.0 $153.6 $123.9
  • Additional KPIs (Q1 2025)
    • Organic revenue growth: +5.0% YoY .
    • Cash from operations: $(19.3)M; drivers were timing of annual bonus and other annual payments (~$27M) .

Guidance Changes

MetricPeriodPrevious (3/11/25)Current (5/6/25)Change
Net SalesFY 2025$560–$570M $560–$570M; tariffs embedded, immaterial Maintained
Adjusted EBITDAFY 2025$112–$116M $112–$116M Maintained
Non‑GAAP EPSFY 2025$0.64–$0.68 $0.64–$0.68 Maintained

Management reiterated a second-half weighted year with at least 100 bps of Adjusted EBITDA margin expansion for 2025 and minimal expected tariff impact (<$1M) .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024)Previous Mentions (Q4 2024)Current Period (Q1 2025)Trend
HA/DUROLANE performance & pricingDouble‑digit HA growth; strong brand; guidance raised HA +17% in Q4; year‑end distributor orders to normalize in Q1 DUROLANE double‑digit growth; CMS ASP +10% YoY but financial ASP slightly positive; volume-led growth Sustained outperformance; temporary Q1 headwinds normalize
Ultrasonics adoptionDouble‑digit growth; pipeline strength Ultrasonics >20% growth; focus on spine near-term Double‑digit growth; strong U.S. capital sales Broadening adoption; capital placements drive growth
Restorative/EXOGENMixed; international pressure EXOGEN returned to growth; plan low–mid single-digit growth Organic growth +4% excluding divestiture; improved sales execution Stable growth after turnaround
Supply chain & FXCost pressures in components in 2024 Inventory write-offs in prior year; supply constraints easing in BGS FX revaluation loss ~$1.1M on SEK; higher freight/channel mix impacted margins Headwinds manageable
Tariffs/macroN/AMonitoring tariffs; macro watch Tariffs embedded and immaterial (<$1M); pharma items currently exempt De‑risked in FY guide
Portfolio updates (PRP, PNS)N/AHighlighted pipeline and execution priorities PRP (APEX XCELL) U.S. distribution signed; 2025 immaterial revenue; PNS tech pending clearance in H2 Added early‑stage growth drivers
International strategyN/ATargeted OUS investments planned; new leader coming New OUS leader started; country-by-country execution focus Building platform for OUS growth

Management Commentary

  • “First quarter revenue of $124 million was in line with our internal expectation and reflected above‑market organic growth of 5%... Adjusted earnings of $0.08 per share increased 33%” .
  • “We continue to strongly believe that our peer‑leading gross margin, combined with the expected acceleration of revenue growth in the second half... will enable us to achieve at least 100 basis points of adjusted EBITDA margin expansion for the year” .
  • “We are reiterating our full‑year revenue, adjusted EBITDA and adjusted earnings per share guidance… we do not see a material impact from tariffs at this time” .
  • CFO: “Adjusted EBITDA of over $19 million was $3 million lower than the prior year… and an unexpected $1.1 million foreign currency loss from the revaluation of payables” .
  • “We ended the quarter with $23 million in cash on hand and $346 million in outstanding debt… expect our net leverage to decrease below 2.5x by the end of 2025” .

Q&A Highlights

  • HA/DUROLANE market and pricing: shift from multi‑ to single‑injection continues; DUROLANE’s clinical differentiation and contracts underpin share gains; CMS ASP +10% YoY vs slightly positive financial ASP; 2025 growth volume‑led with stable pricing overall .
  • Pain Treatments cadence: Q2 faces tough comp (prior competitor supply issues, favorable rebate accruals); recent account wins support H2 acceleration .
  • Tariffs: pharma currently excluded; total tariff impact embedded in guidance and minimal; company monitoring scenario plans .
  • Outlook & leverage: confidence in 2Q–4Q acceleration; EBITDA step‑up similar to 2024; leverage targeted to ~2.5x by YE25 .
  • M&A and capital allocation: focus on deleveraging below 2x over time; selective on portfolio expansions (e.g., PRP) that fit mission and footprint .
  • International leadership: new leader in place; focus on prioritized country/product roadmap and commercial execution .

Estimates Context

  • Q1 2025 performance versus S&P Global consensus: revenue $123.9M vs $122.7M* and Non‑GAAP EPS $0.08 vs $0.023*; both beats, driven by DUROLANE and Ultrasonics strength, with temporary distributor normalization and FX loss offsetting some upside .
  • Given reiterated FY guide and H2‑weighted cadence, street models may need to reflect: (a) minimal tariff impact (<$1M), (b) H2 acceleration in HA and BGS, (c) modest gross margin pressure from mix/freight in H1 normalizing thereafter .
    Values retrieved from S&P Global.*

Key Takeaways for Investors

  • H2 acceleration remains the core narrative: temporary Q1 headwinds (channel normalization, two fewer selling days, FX) are transitory; management confidence and guide reaffirmation support a back‑half setup .
  • Structural share gains in DUROLANE and Ultrasonics continue; expect volume‑driven growth in HA and broadening Ultrasonics adoption to sustain above‑market revenue growth .
  • Margin framework intact: despite Q1 mix/freight pressure and FX, company still targets ≥100 bps Adjusted EBITDA margin expansion for FY25 .
  • Cash and leverage trajectory favorable: operating cash flow expected to inflect from Q2 onward; net leverage targeted to ≤2.5x by YE25, enhancing strategic flexibility .
  • Portfolio optionality: PRP adds a synergistic adjacency with limited 2025 P&L impact; peripheral nerve stimulation technology potentially adds a mid‑term growth lever post‑clearance .
  • Watch international execution: new leadership and targeted OUS strategy could unlock incremental growth over time .
  • Risk checks: reimbursement/regulatory (e.g., bone growth stimulator down‑classification) and macro/tariff dynamics appear contained in guide but warrant monitoring .

Appendix: Detailed Financials and Disclosures

  • Q1 2025 highlights: revenue $123.876M (‑4.3% YoY), organic revenue +5.0%, Adjusted EBITDA $19.212M, GAAP EPS $(0.04), Non‑GAAP EPS $0.08, GAAP GM 67.0%, Non‑GAAP GM 75.3% .
  • Segment color: Pain +3.9% to $58.9M (DUROLANE double‑digit; some distributor destocking), Surgical +7.0% to $45.2M (Ultrasonics strong), Restorative down 35.3% reported (divestiture) but +4% organic (EXOGEN execution) .
  • Cash flow: CFO identified ~$27M timing items (bonuses, insurance) driving Q1 outflow; excluding these, operating cash flow would have been positive .

Citations:

  • Q1 2025 8‑K/Press Release and exhibits .
  • Q1 2025 Press Release duplicate (GlobeNewswire) .
  • Q1 2025 Earnings Call Transcript .
  • Q4 2024 Press Release .
  • Q4 2024 Earnings Call Transcript .
  • Q3 2024 Press Release .

Notes:

  • Non‑GAAP metrics and reconciliations are provided by the company in the referenced materials .
  • Values retrieved from S&P Global.*